AVPR2 and Hyponatremia: In 2009, tolvaptan—a specific V2R antagonist—was approved by the Food and Drug Administration (FDA) for the treatment of euvolemic and hypervolemic hyponatremia associated with heart failure, cirrhosis, and SIADH (syndrome of inappropriate antidiuretic hormone secretion) [7,8,9].